Archive for July 25th, 2012

CRTX Advisory Committee date set. MAPP Levadex NDA update. ZGNX offering + updates for ITMN MDVN AEZS DVAX NKTR CADX

Jul 25, 2012 No Comments by

Cornerstone Therapeutics, Inc. (NASDAQ:CRTX) – The Cardiovascular and Renal Drugs Advisory Committee will meet on September 13, 2012, to discuss the NDA of lixivaptan, for the proposed indication of the treatment of symptomatic hypervolemic and euvolemic hyponatremia associated with heart failure and syndrome of inappropriate antidiuretic hormone (SIADH), respectively. MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) said it hopes to resubmit its NDA of LEVADEX for the […]

Daily News Read more